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RhoBTB Proteins Regulate the Hippo Pathway by
Antagonizing Ubiquitination of LKB1
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ABSTRACT The Hippo pathway regulates growth and apoptosis. We identify RhoBTB proteins as novel
regulators of Hippo signaling. RhoBTB depletion in the Drosophila wing disc epithelium cooperated with Yki
to drive hyperplasia into neoplasia. Depletion of RhoBTB2 caused elevated YAP activity in human cells.
RhoBTB2 deficiency resulted in increased colony formation in assays for anchorage-independent growth. We
provide evidence that RhoBTBs acts on Hippo signaling through regulation of the kinase LKB1. LKB1 protein
levels were reduced upon RhoBTB2 depletion, which correlated with increased LKB1 ubiquitination.
Restoring LKB1 levels rescued loss of RhoBTB in Drosophila. Our results suggest that RhoBTB-dependent
LKB1 regulation may contribute to its tumor-suppressive function.
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First discovered in Drosophila, the Hippo pathway has emerged as an
important regulatory network controlling cell proliferation and organ
size (Yu et al. 2015). It is further involved in tissue homeostasis and
embryonic cell fate specification. Hippo signaling serves as a barrier
for oncogenic transformation, highlighting the role of this pathway in
regulating cancer development and progression (Zhao et al. 2007;
Nguyen et al. 2014). The pathway is comprised of a core-cassette of
tumor suppressors which act in a phosphorylation cascade to regulate
the activity of the transcription factor YKI. Many core components of
the pathway have been originally identified in Drosophila (Justice
et al. 1995; T. Xu et al. 1995; Harvey et al. 2003; Udan et al. 2003;
Harvey et al. 2013). A significant number of elements of the Hippo
pathway are conserved between mammals and Drosophila mela-
nogaster (Yu et al. 2015; Pfleger 2017). The mammalian pathway
consists of a core cassette comprising the upstream kinases MST1/2
(Hpo in Drosophila) and the downstream kinases LATS1/2 (Wts in
Drosophila). SAV1 (Sav in Drosophila) acts as a scaffold protein and
assists in the interaction between the upstream and downstream
kinases. MOB1 (Mats in Drosophila) plays a critical role in regulating
LATS kinase activity. Activation of Hippo signaling induces the
MST-dependent phosphorylation of LATS1/2 and subsequent phos-
phorylation of proto-oncogenes YAP and TAZ (Yki in Drosophila).
When not phosphorylated by the Hippo core cassette, YAP/TAZ/
Yki translocate to the nucleus and associate with transcriptional
regulators including those of the TEAD family to induce gene
expression (Lin et al. 2017). Consequently, Hippo pathway activ-
ity inhibits YAP/TAZ/Yki target gene expression. Dysregulation
of YAP or TAZ activity has been correlated with tumorigenesis
(Moroishi et al. 2015).
RhoBTB proteins, which include the highly similar RhoBTB1,
RhoBTB2 and RhoBTB3 isoforms in human and a single RhoBTB
gene in Drosophila, are atypical members of the Rho family. In
addition to the typical GTPase domain characteristic for the Rho
family, all RhoBTB proteins share a proline-rich region, two tandem
broad complex, tramtrack and bric-à-brac (BTB) domains that were
originally identified as motifs present in several transcription regu-
lators inDrosophila, and a conserved C-terminus. Unlike the majority
of other Rho family members, RhoBTB proteins do not seem to
regulate the actin cytoskeleton directly (Aspenström et al. 2004).
Instead they have been found to function through diverse molecular
mechanisms (Berthold et al. 2008), including as substrate-specific
adaptors for CUL3-based E3 ubiquitin ligase complexes. RhoBTB
proteins have been implicated in mediating a variety of biological
functions, including the oxidative stress response, cytoskeletal or-
ganization, apoptosis and Hedgehog signaling (Kobayashi et al.
2004; Zhang et al. 2006; Chen et al. 2009; Jin et al. 2009). Recent
evidence suggests that RhoBTB proteins are deregulated in some
human cancers. RhoBTB2, for example, was reported to be homo-
zygously deleted in a large percentage of breast cancer tumors
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(Hamaguchi et al. 2002; Mao et al. 2009). Downregulation of
RhoBTB2 was further observed in lung, bladder, bone and gastric
cancer (Cho et al. 2009; Shi et al. 2008; Dong et al. 2012; Jin et al.
2013). Obtained in breast cancer cells, evidence suggests that
RhoBTB2 exerts a tumor-suppressive function by inhibiting cancer
cell proliferation, migration and invasiveness (Ling et al. 2014; Mao
et al. 2011). Similar anti-tumorigenic properties were also found for
the other RhoBTB isoforms. RhoBTB1 was found heterozygously
deleted in head and neck tumors (Beder et al. 2005) and colon
cancer (Xu et al. 2013). RhoBTB3 expression was greatly reduced in
renal carcinoma and acts as a tumor suppressor through promoting
ubiquitination and degradation of HIFa (Zhang et al. 2015).
Here, we provide evidence that RhoBTB proteins behave as tumor
suppressors by regulating Hippo pathway activity in Drosophila
and human cells. We show that RhoBTB2 acts via ubiquitination-
dependent regulation of LKB1. Our work illustrates a novel aspect of
the multifaceted molecular function of RhoBTB proteins.
MATERIALS AND METHODS
Drosophila genetics and immunocytochemistry
The use of Drosophila imaginal wing discs as a model for epithelial
tumor formation was previously described (Herranz et al. 2012; Song
et al. 2017; Herranz & Cohen 2017). RhoBTB was a validated
candidate from a genome-wide screen identifying tumor suppressors
whose knockdown promoted oncogenic activity of Yki as a tumor
driver in Drosophila (Groth et al. 2019 preprint).
Briefly, male flies from the KK transgenic RNAi stock library of
the Vienna Drosophila RNAi Center (VDRC, www.vdrc.at) carrying
four different inducible UAS-RNAi constructs (P{TRiP.HMC02368}
attP40/CyO, P{TRiP.HMC03199}attP40, P{TRiP.HMS00411}attP,
P{KK100815}VIE-260B, P{VSH330130}attP40) targeting RhoBTB
were crossed to 10-15 virgins from the Yki driver stock used in the
screen with the following genotype:w, ap-Gal4, UAS-GFP/CyO;UAS-
Yki, tub-Gal80ts/TM6B. Crosses were carried out at 18 and flipped to
new vials after 3 days. On day 11 post-mating, larvae-containing vials
were moved to a 29 incubator to induce Yki expression. Crosses were
left at 29 for another 9 days and larvae were scored for size and wing
disc overgrowth phenotypes on the day 20 post-crossing (induction
day 10). Other fly crosses were conducted using the same protocol.
All other RNAi transgenic lines including P{VSH330167}attP40
(GD), P{KK108675}VIE-260B (attP40), P{TRiP.GL00019}attP2,
P{TRiP.HMS01351}attP2 (targeting LKB1) and control lines were
obtained from VDRC. The UAS-LKB1 (wild type) and UAS-LKB1
(KI) fly strains (Mohseni et al. 2014) were a kind gift of Jongkyeong
Chung.
Imaginal wing discs were dissected and processed as described
(Song et al. 2017). Antibodies were mouse anti-MMP-1 (1:10, DSHB,
3A6B4/5H7B11/3B8D12 were mixed in equal amounts), mouse anti-
Dlg (1:200, DSHB, 4F3) and rat-anti-DE-Cadherin (1:100, DSHB,
DCAD2).
Plasmids, siRNAs and shRNAs
8xGTIIC-luciferase was a gift from Stefano Piccolo (Addgene plasmid
#34615). The pRL-CMV (Renilla, #E2261) was purchased from
Promega (Madison, WI, USA). Smart pool siRNAs against RhoBTB2
were obtained from Dharmacon. shRNAs against RhoBTB2 were
expressed from the pSuper expression vector (Brummelkamp 2002)
with target sequences as listed in the Supplemental Table 1. RASG12V
and LATS2 shRNA constructs were described previously (Voorhoeve
et al. 2006).
Quantitative reverse transcriptase PCR (qPCR)
RNA was extracted using Trizol (Invitrogen) and cDNA was pre-
pared using the iScript cDNA synthesis kit (Biorad) with random
hexamers following the manufacturer’s instructions. Specific primers
used for RT-PCR are listed in Supplemental Table 1. qPCR was
performed using the Solis BioDyne Firepol qPCRMaster Mix and the
Biorad 2X SYBR Green Master Mix.
Luciferase assay
Luciferase assay to measure YAP/TAZ activity were performed using
a dual luciferase kit (E1960, Promega) according to the manufac-
turer’s instructions and as previously described (Nguyen et al. 2017).
Cell culture experiments
All cell lines were purchased from the ATCC and cultured under
standard conditions. All cell-based assays were performed as described
(Nguyen et al. 2017; Nguyen et al. 2016). YAP localization was scored
using mouse-anti-YAP (sc-101199, Santa Cruz) as previously described
(Nguyen et al. 2017). Antibodies to phospho-YAP Ser127 (Cat #4911),
YAP (#4912), TAZ (#2149), LATS2 #5888), phospho-LATS1/2 (#8654),
Myc-Tag (#2272), LKB1 (#3050), MARK1 (#3319) and p-MARK1-4
(#4386) were from Cell Signaling. YAP (#sc-101199) antibody used for
immunohistochemical staining was obtained from Santa Cruz Biotech-
nology. Anti-FLAG (M2, #F3165) and RhoBTB2 (SAB1407189) were
from Sigma. Anti-actin (#MAB1501) was from Millipore.
Data availability
Strains and plasmids are available upon request. The authors affirm
that all data necessary for confirming the conclusions of the article
are present within the article, figures, supplementary figures and
tables. Supplementary figures were uploaded to figshare. Supplemen-
tal Table S1 contains primer and shRNA sequences. Supplementary
figure S1 shows phenotypes caused by additional RNAi lines used in
the study. Supplementary figure S2 illustrates how YAP nuclear
localization was scored. Supplementary figure S3 shows results of
colony formation assays using cancer cell lines. Supplemental mate-
rial available at figshare: https://doi.org/10.25387/g3.11894592.
RESULTS AND DISCUSSION
Depletion of RhoBTB cooperates with Yki in a Drosophila
epithelial transformation model
RhoBTB proteins perform a variety of molecular functions and can
target proteins for proteasomal degradation (Choi et al. 2016). To
study whether RhoBTB activity can regulate the Hippo pathway, we
used a Drosophila epithelial tumor model (Song et al. 2017) which
allows the spatio-temporally controlled expression of transgenes. In
this system, conditional expression of Yki leads to mild hyperplasia in
the imaginal wing disc epithelium (Figure 1A). RNAi-mediated
RhoBTB depletion had little or no effect on its own (Figure 1A).
However, co-expression of Yki with several independent RhoBTB-
targeting RNAi transgenes caused formation of massively overgrown
tumors in a subset of larvae (Figure 1A and Suppl. Fig. S1). On
average 3-4 phenotypically noticeable larvae were observed per vial.
These larvae were developmentally delayed but did not display the
characteristic ‘giant larvae’ phenotype often associated with tumor-
igenesis in Drosophila. Tumor formation did not occur at high
frequency, but was consistently observed in replicate experiments,
independent crosses and with different RNAi lines targeting RhoBTB,
arguing against off-target effects. The relatively low frequency of
tumor-bearing larvae might be due to only partial efficiency of the
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transgenes targeting RhoBTB as well as due to competition with sibling
larvae with non-inducing genotypes under crowded conditions.
Tumors did neither exhibit evident loss of polarity as assessed by
several markers (DE-Cadherin, Dlg and actin), nor upregulation of
Matrix Metalloprotease-1 (MMP1) (Figure 1A). Based on these
observations, we decided to test whether interactions between
RhoBTB activity and the Hippo pathway might be a conserved
feature in human cells.
YAP activity and YAP target expression are influenced
by RhoBTB2 in human cells
YAP and TAZ are the mammalian orthologs of Drosophila Yki
(Huang et al. 2005). To test whether modulation of RhoBTB
activity would impact on the Hippo pathway, we utilized a
luciferase reporter containing octameric TEAD binding sites in
HEK293T cells. In these cells, the reporter responds sensitively to
perturbations of YAP and TAZ activity (Dupont et al. 2011;
Nguyen et al. 2016). HEK293T cells express high levels of
RhoBTB2. Of note, HEK293T and the other cell lines used in this
study expressed very low levels of RhoBTB1mRNA as compared to
RhoBTB2 and undetectable levels of RhoBTB3 (data not shown).
Three independent RhoBTB2 shRNAs, which strongly reduced
RhoBTB2 expression but had little or no effect on RhoBTB1
(Figure 1B), strongly induced reporter activity (Figure 1C). Con-
sistently, several endogenous transcriptional YAP targets (CTGF,
AREG an CYR61) were upregulated upon depletion of RhoBTB2,
while there was no change in YAP mRNA levels (Figure 1B).
Taken together, these results indicate that RhoBTB2 possibly
influences YAP activity post-transcriptionally through regulating
the Hippo pathway.
YAP is post-transcriptionally regulated by RhoBTB2
Upon phosphorylation by the Hippo pathway core cassette compo-
nents LATS1 and LATS2, YAP is retained in the cytoplasm and
Figure 1 RhoBTB regulates the Hippo pathway.
(A) Representative images showing the synergistic
effect between Yki overexpression and RhoBTB
depletion in a Drosophila transformation model.
Genotypes are indicated in the figure. DAPI (blue),
GFP (green), DE-Cadherin (red). MMP1 staining is
shown as a separate panel (white). The rightmost
image shows a representative Y-Z projection illus-
trating the epithelial polarity of the adjacent tu-
mor (DE-Cadherin, red). (B) qPCR quantification of
RhoBTB2, YAP, and YAP-targets CTGF, AREG
and CYR61 in HEK293T cells treated with a control
shRNA or three independent shRNAs targeting
RhoBTB2. Changes in CTGF, AREG and CYR61
were significant in RhoBTB2 shRNAs-depleted cells
compared to the control (ANOVA P , 0.001). Error
bars represent mean +/2 SD for three independent
experiments. (C) Luciferase reporter assays per-
formed in HEK293T cells treated with a control
shRNA or three independent shRNAs targeting
RhoBTB2. Changes in luciferase activity were
significant in all shRNAs vs. control (ANOVA
P , 0.0001). Error bars represent mean +/2 SD
for three independent experiments. (D) Scoring of
nuclear YAP localization in BJ cells treated with a
scrambled control siRNA (black bars) or a siRNA
pool targeting RhoBTB2 (gray bars). Changes in
number of cells exhibiting high and low nuclear
YAP were significant in RhoBTB2 shRNA express-
ing vs. control cells (ANOVA P , 0.01). (E) West-
ern blots of cellular extracts from cells treatedwith
a control shRNA or two different shRNAs target-
ing RhoBTB2. Blots were probed with antibodies
specific for phospho-LATS1/2 (T1079), LATS 2,
phospho-YAP (S127), YAP, TAZ. ACTIN was used
as a loading control. Grayscale values of inverted
bands measured with ImageJ and normalized
against ACTIN are shown above the correspond-
ing bands to indicate the band intensities.
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ultimately targeted for degradation (Zhao et al. 2010). In contrast, non-
phosphorylated YAP translocates to the nucleus to activate target gene
expression. Since knockdown of RhoBTB2 led to an increase of YAP/
TAZ activity, we asked whether RhoBTB2 inhibition would affect the
subcellular localization of YAP. We utilized a previously established
fibroblast cellmodel expressing humanTERT, p53 shRNA, p16 shRNA
and RASG12V (BJhTert/p53kd/p16kd/RASG12V) that permits detecting YAP
translocation by immunochemical staining of YAP upon inhibi-
tion of the Hippo pathway (Nguyen et al. 2017). In comparison to
control cells, RhoBTB2 depletion caused a statistically significant
shift toward increased nuclear YAP levels (Figure 1D and Suppl.
Fig. S2). We next assessed the expression and phosphorylation of
Hippo proteins in the context of RhoBTB2 depletion in these cells
by Western blot analysis. Knockdown of RhoBTB2 using two
different shRNAs lead to an increase in the protein level of
YAP and TAZ ($ 1.fivefold increase in protein levels, which
correlated with reduced phosphorylation of YAP (p-Ser127: re-
duced by more than 0.5 fold) (Figure 1E). LATS2 protein levels did
not change or increased slightly (1.twofold). In contrast, we
observed a more than twofold reduction of LATS phosphorylation,
consistent with reduced LATS activity.
Taken together, these data are consistent with the idea that RhoBTB2
deficiency prevents the Hippo core cassette from phosphorylating YAP,
which would consequently promote transcription of target genes in
the nucleus. Therefore, our results suggest that RhoBTB2 regu-
lates YAP at the post-transcriptional level through the Hippo core
cassette.
RhoBTB2 inhibits cell growth by regulating Hippo
pathway activity
Active YAP can promote cell proliferation and growth via transcriptional
regulation of numerous target genes (Zhao et al. 2007; Ehmer & Sage
2016). We therefore asked whether depletion of RhoBTB2 would cause
phenotypes associated with increased YAP activity. To address this
question, we studied the effect of RhBTB2 suppression on colony
formation in soft agar in two partially transformed human fibroblast
cell models expressing human TERT, p53 shRNA, p16 shRNA and small
T (BJhTert/p53kd/p16kd/small t) or RASG12V (BJhTert/p53kd/p16kd/RASG12V).
These genetically defined cells were previously shown to be sensitive
to perturbations of YAP activity, which is coordinately regulated by the
Hippo and RAS pathways (Nguyen et al. 2014; Hong et al. 2014). As
expected, expression of active RAS (Figure 2A) or depletion of LATS2
(Figure 2B), which induces YAP activation, caused enhanced trans-
formation phenotypes upon inhibition of Hippo activity. Depletion of
RhoBTB2 in these cell lines increased anchorage-independent growth in
soft agar assays (Figure 2A and 2B). These data are consistent with the
Figure 2 RhoBTB2-depletion enhances anchorage-independent growth in soft agar assay. (A, B) Colonies formed in soft agar by partially
transformed BJ cells (genotypes indicated in the figures) treated with either a control shRNA, or shRNAs targeting RhoBTB2. Upper panels:
representative images. Lower panels: Graphs showing number of colonies per image from three experiments of independently transduced cells.
RASG12V and LATS2 shRNA were used as positive controls for each cell model. Changes in colony number were significant in RASG12V and all
shRNA-expressing vs. control cells (ANOVA P , 0.01). Error bars represent mean +/2 SD for three independent experiments.
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idea that RhoBTB2 controls cell growth and proliferation by modulating
Hippo pathway activity.
We observed a similar growth-suppressive behavior of RhoBTB2 in
several cancer cell lines. Depletion of RhoBTB2 led to an increase in
colony formation in the cell lines HT-15, MDA-MB-468, HeLa,
HCT116 and HT-29 (Suppl. Fig. S3). The cell lines MDA-MB-231,
DU-145, A549 and H1299 did not display a change in colony numbers.
Surprisingly, MCF-7 cells showed reduced cell growth when RhoBTB2
was depleted (data not shown). The role of RhoBTB2 in these cell lines
remains unclear. Taken together, however, these results suggest that
RhoBTB2 could be part of the machinery that limits proliferation of
cancer cells, depending on the specific cellular context.
Figure 3 RhoBTB2 depletion affects the Hippo
pathway through the LKB1/MARK axis. (A) Western
blots of HEK293T cells transfected with a control
shRNA or two independent shRNAs targeting
RhoBTB2. Blots were probed for LKB1, phospho-
MARK1-4 and MARK1 antibodies. ACTIN was used
as a loading control. Grayscale values of inverted
bands measured with ImageJ and normalized
against ACTIN are shown above the corresponding
bands to indicate the band intensities. (B) Ubiquiti-
nation assay of cells transfected with myc-Ubiquitin,
FLAG-LKB1 and either a scrambled siRNA pool, or
with a siRNA pool targeting RhoBTB2. Blots were
probed with anti-myc and anti-FLAG.
Figure 4 LKB1 resupply suppresses tu-
mor formation induced by depletion of
RhoBTB2. (A) Confocal images of wing
discs showing the effect of LKB1 de-
pletion. GFP (green), DAPI (blue) and
Dlg (red). Genotypes are indicated in
the figure. All images correspond to the
same scale. (B) Representative images
of wing discs showing the influence of
wildtype LKB1 overexpression respec-
tively kinase-inactive LKB1 expression
on the RhoBTB2 depletion phenotype.
Discs were stained for actin. Genotypes
are indicated. All images were taken at
the samemagnification. (C) Graphs show-
ing the effect of wildtype LKB1 (LKB1WT)
overexpression respectively kinase-inac-
tive LKB1 (LKB1KI) expression on the fre-
quency of wing disc tumor formation.
Data are presented as the number of
tumor-bearing larvae scored per day
6 SD p-values were determined using
a non-parametric Mann-Whitney test.
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RhoBTB2 acts on the Hippo pathway via regulation
of LKB1
To elucidate how RhoBTB2 regulates Hippo signaling, we searched
the BioGRID database (Oughtred et al. 2018) for potential interaction
partners. This approach identified the kinase LKB1 (also known
as STK11) as a candidate RhoBTB2 interactor. LKB1 acts on the
Hippo pathway via phosphorylation of MARK kinases and thereby
modulates YAP activity to regulate organ growth and proliferation
(Mohseni et al. 2014). We observed reduced LKB1 expression
($ threefold) and MARK phosphorylation (40% reduction) in
RhoBTB2-depleted cells (Figure 3A). Since LKB1 is a known substrate
of the Skp2-SCF ubiquination complex that targets several Hippo
components (Lee et al. 2015), we asked if RhoBTB2 depletion would
affect LKB1 ubiquitination. Consistent with the reduced LKB1 levels,
LKB1 was more extensively ubiquitinated in RhoBTB2-depleted cells
than in the control (Figure 3B). These data are consistent with the
idea that RhoBTB2 impacts on Hippo pathway activity through the
LKB1/MARK axis.
Resupply of LKB1 rescues tumor formation induced by
RhoBTB depletion
Depletion of RhoBTB drives Yki-mediated hyperplasia into tumor
formation (Figure 1A). To test whether a decrease in LKB1 levels
produces a similar effect, we depleted LKB1 in the Drosophila wing
disk epithelium using several independent RNAi lines. Concomitant
with Yki overexpression, but not on its own, LKB1 depletion led to the
formation of larvae bearing large tumors (Figure 4A). We did neither
detect a loss of epithelial polarity nor significant changes in MMP-1
levels or occurrence of giant larvae (not shown). The phenotypical
similarities between individuals depleted for RhoBTB and LKB1
strengthen the idea that RhoBTB acts on the Hippo pathway via
regulation of LKB1.
The above-described results prompted us to investigate whether
resupply of LKB1 could rescue tumor formation induced by RhoBTB
depletion. We therefore transgenically elevated LKB1 levels in
RhoBTB-depleted larvae overexpressing Yki. Addback of wildtype
LKB1 was correlated with a lower frequency of tumor-bearing
larvae while expression of a kinase-inactive form of LKB1 did not
rescue tumor formation (Figure 4B and 4C). We further examined
the morphology of wing disc tumors and observed phenotypic suppres-
sion in a substantial fraction of the individuals overexpressing wildtype
LKB1. No suppression was obvious when overexpressing kinase-inactive
LKB1. These data demonstrate that LKB1 can compensate for loss of
RhoBTB function, supporting the hypothesis that RhoBTB proteins
regulate Hippo signaling through mediating LKB1 turnover.
Based on our data, we cannot rule out that LKB1 affects growth
independent of Yki/YAP/TAZ. However, given that RhoBTB de-
pletion clearly affects core components of the Hippo pathway, and
that LKB depletion on its own does not affect growth in the imaginal
wing disk but requires elevated Yki levels to drive tumor formation,
the most parsimonious model suggests that RhoBTB proteins
impact on growth through the Hippo pathway by ultimately influ-
encing Yki/YAP/TAZ abundance and activity. We cannot rule out
that LKB1 acts on growth through additional mechanisms that do not
impact on Yki/YAP/TAZ.
In this study, we have provided evidence that RhoBTB proteins
may modulate Hippo pathway activity via regulation of LKB1. Our
results indicate that RhoBTB2 plays a regulatory role in a ubiq-
uitination cascade acting on LKB1, thereby preventing its ubiquiti-
nation and subsequent proteasomal degradation. These findings
provide insights into the tumor-suppressive function of RhoBTB
proteins and into the upstream signaling processes controlling the
Hippo pathway.
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